Cellular Exploration of Potential Synthetic Compounds for Advancing Drug Development in Psoriasis

Abstract

Psoriasis is a prevalent chronic autoimmune inflammatory skin disease affecting over 125 million individuals globally, posing a significant health challenge. Investigating synthetic compounds featuring the 1,2,3-triazole structure known for their anti-inflammatory effects, this research aimed to evaluate synthetic drug compound candidates for their anti-inflammatory properties. The assessmentsinvolved cytokine production and cytotoxicity assays using human keratinocyte (HaCaT) and macrophage (THP- 1) cell models. The results demonstrated that all the tested synthetic compounds were non-toxic and

capable of effectively inhibiting the expression of IL-6, IL-8, and TNF-α in the inflammation-induced cell lines. Notably, CCL-7040n stood out by showcasing inhibitory effects towards all three critical cytokines in the macrophage model, as well as IL-8 in the keratinocyte model. Further research is needed to

elucidate the precise mechanisms of action, evaluate the effects on a broader panel of psoriasis- relevant cytokines, and validate the therapeutic potential in vivo. Nonetheless, the findings highlighted the non-toxic and promising anti-inflammatory properties of the 1,2,3-triazole-based synthetic compounds, positioning them as potential therapeutic candidates for the management of psoriasis.